Three Red Flags in CRO Proposals That Predict Headaches Later

The best-looking proposal is often the least revealing.

A polished deck tells you how well a CRO sells.  It doesn't tell you how that CRO will behave halfway through the projected timeline, when enrollment is 40% behind forecast, sites have stopped enrolling, and your data manager just flagged a query backlog you can't explain to your board.

The signals are already there. They're in the language the CRO uses.

Here are three I look for:

📡1. Vague team-continuity commitments

Impressive CVs are not the same as sustained access to the people who will actually run your study.  Named experts often appear in the pitch and disappear after award.  Reassigned, oversubscribed, or "supporting" your program from a distance.  The proposal usually reveals this through softness: "anticipated," "representative," "subject to availability."

Ask:  "Which roles are fully committed at award, what percentage of each person's time is reserved for this study, and what is your replacement and transition process if a named leader leaves the organization?"

🛰️2. Generic governance language

"Robust governance."  "Collaborative partnership."  "Proactive communication."  These phrases cost nothing to write and mean nothing under pressure.  Governance is only real when it's tied to decision rights, escalation pathways, metrics, cadence, and named accountability. 

Ask:  "Show us the governance model you would use for our study:  who attends each forum, which decisions are made there, what triggers escalation, and how quickly are issues expected to be resolved?"

📶3. Misaligned recruitment or monitoring assumptions

Aggressive enrollment curves and thin monitoring models make a bid look competitive.  They also transfer risk directly onto you as change orders, protocol deviations, data-quality remediation, and timeline slippage.  A proposal that assumes everything goes right is merely a statement of optimism…not a plan.

Ask:  "What assumptions drive your recruitment timeline and monitoring intensity, and how would the plan change if enrollment, site performance, or data-risk indicators differ from forecast?"

These are prompts for a biotech or emerging biopharma to probe harder before signature.  Some CROs answer these questions with precision and candor, including where their assumptions are fragile.  That real answer is worth more than a flawless deck.

Operational excellence doesn't show up in promises.  It shows up in specificity, transparency, realistic assumptions, and a credible response when conditions change.

Part of my CRO selection support is helping sponsors see beyond the slide deck and into how the CRO will actually operate when your study is under pressure.

The best-looking proposal is rarely the most revealing one. ABRA reads them alongside sponsors, as part of CRO selection and proposal evaluation.